Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.2410 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Li Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Economics Unit, The University of Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Probiotics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Importance The first peanut oral immunotherapy (OIT) for children was approved by the US Food and Drug Administration (FDA) in 2020. While clinical efficacy is established, evidence on cost-effectiveness—whether the benefits outweigh the costs and adverse effects—remains limited. A variant of OIT, known as probiotic and peanut OIT (PPOIT), has shown similar efficacy in trials.
Objective
To compare the cost-effectiveness of PPOIT, OIT, and no treatment. Design, Setting, and Participants This economic evaluation was conducted alongside a multicenter, randomized, placebo-controlled clinical trial in Australia between 2016 and 2019. Time horizon was 10 years, including 1.5 years of active treatment, 2 years of posttreatment follow-up, and 6.5 years of extrapolation. Data were analyzed from May 2024 to August 2025.
Interventions
PPOIT and OIT. Main Outcomes and Measures Effectiveness was measured using remission achieved and patient quality-adjusted life years (QALYs) gained. Costs were evaluated from a health care payer perspective, including active treatment and adverse event costs, and were calculated in Australian dollars. Incremental cost-effectiveness ratios were estimated. Sensitivity analyses were conducted to capture uncertainty.
Results
A total of 201 children aged 1 to 10 years were recruited, 79 in PPOIT, 83 in OIT, and 39 in no treatment (mean [SD] age, 5.9 [2.8] years; 129 [64.2%] male). Over a 10-year horizon, mean (SD) cost per patient was A$3956 (A$67) for PPOIT (treatment, A$3579 [A$0]; adverse events, A$377 [A$67]), A$3582 [A$57] for OIT (treatment, A$3179 [A$0]; adverse events, A$402 [A$57]), and A$249 (A$87) for no treatment (treatment, A$0 [A$0]; adverse events, A$249 [A$87]). Mean (SD) annual remission was 34.1% (12.7%) for PPOIT, 35.1% (15.4%) for OIT, and 7.3% (8.1%) for no treatment. The total QALYs gained for PPOIIT, OIT, and no treatment were 0.096, 0.055, and 0, respectively. PPOIT was slightly more costly than OIT, achieved similar remission, and achieved better quality-of-life. Compared with no treatment, both treatments were more costly with minor risks, achieved higher remission (PPOIT, A$1384; 95% CI, A$1269-A$1415; and OIT, A$1199; 95% CI, A$1091-A$1217 per year of remission achieved, respectively), and improved quality of life (PPOIT, A$38 435; 95% CI, A$31 058-A$48 668 and OIT, A$60 840; 95% CI, A$49 479-A$86 531 per QALY gained, respectively). Conclusions and Relevance This economic evaluation found that for remission, both PPOIT and OIT were cost-effective and good value compared with no treatment, with OIT associated with a larger effect size but no clinically meaningful difference. When QALYs are prioritized, PPOIT offers the best value. Key factors associated with cost-effectiveness were treatment product pricing and patient quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Child Health Economics Unit, The University of Melbourne, Victoria, Australia.
- Allergy Immunology, Murdoch Children's Research Institute, Victoria, Australia.
- Health Economics and Policy Evaluation Research, Monash Institute of Pharmaceutical Sciences, Victoria, Australia.
- Department of Paediatrics, The University of Melbourne, Victoria, Australia.
- Immunology Department, Perth Children's Hospital, Western Australia, Australia.
- Division of Paediatrics, The University of Western Australia, Western Australia, Australia.
Zitieren
APA
Huang, L., Lloyd, M., Franz, A., Loke, P., O'Sullivan, M., Gold, M., Quinn, P., Tang, M. L. K., & Dalziel, K. (2026). Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.2410
Vancouver
Huang L, Lloyd M, Franz A, Loke P, O'Sullivan M, Gold M, et al. Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.2410
BibTeX
@article{Huang2026,
author = {Huang, Li and Lloyd, Melanie and Franz, Adam and Loke, Paxton and O'Sullivan, Michael and Gold, Michael and Quinn, Patrick and Tang, Mimi L K and Dalziel, Kim},
title = {Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.2410}
}
EUVIMED